Unveiling 4 Analyst Insights On TScan Therapeutics
Unveiling 4 Analyst Insights On TScan Therapeutics
公佈關於tScan療法的4項分析師見解
TScan Therapeutics (NASDAQ:TCRX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
TScan Therapeutics（納斯達克股票代碼：TCRX）在上個季度接受了4位分析師的分析，揭示了從看漲到看跌的一系列觀點。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
Analysts have recently evaluated TScan Therapeutics and provided 12-month price targets. The average target is $10.75, accompanied by a high estimate of $15.00 and a low estimate of $9.00. Surpassing the previous average price target of $7.00, the current average has increased by 53.57%.
分析師最近對tScan Therapeutics進行了評估，並提供了12個月的目標股價。平均目標爲10.75美元，最高估計值爲15.00美元，低估值爲9.00美元。超過了之前的平均目標股價7.00美元，目前的平均價格上漲了53.57％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
The...
通...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。